The epidemiology of Anaerococcus murdochii remains relatively understudied, and the understanding of its prevalence is limited. This anaerobic bacterium has been documented primarily in cases of skin and wound infections. Moreover, reports of resistance or reduced susceptibility to several antibiotics, including colistin sulfate, clindamycin, kanamycin A, and penicillin, underscore the importance of careful antibiotic selection in treating A. murdochii infections.
Several studies have attempted to shed light on the occurrence of A. murdochii in clinical specimens. For instance, a study conducted in Denmark found that A. murdochii was isolated from approximately 0.4% of 1,111 clinical specimens collected from patients suspected of having anaerobic infections.
Similar studies from Japan and China reported lower isolation rates, with A. murdochii detected in approximately 0.3% of 1,200 specimens in Japan and 0.2% of 500 specimens in China. These specimens were collected from various anatomical sites, including skin, soft tissue, bone, joints, blood, and other anatomical regions. Notably, there have been no documented outbreaks or epidemics of A. murdochii infections in the literature.
Classification and Structure:
Kingdom: Bacteria
Phylum: Bacillota
Class: Clostridia
Order: Eubacteriales
Family: Peptoniphilaceae
Genus: Anaerococcus
Species: A. murdochii
Anaerococcus murdochii is a gram-positive, anaerobic coccus or GPAC pathogen commonly found in the human microbiome. Its cells are non-motile and non-spore-forming and can be arranged in pairs, tetrads, short chains, or irregular clusters.
The cell size of A. murdochii can vary, typically ranging from 0.6 μm to 0.9 μm, but it can extend from 0.5 μm to 2 μm. Major cellular fatty acids in A. murdochii include C18:1, C16:1, C18, and C16.
Anaerococcus murdochii exhibits various surface determinants, including peptidoglycan, teichoic acid, and lipoteichoic acid, essential components contributing to its structure and interaction with the host immune system. Depending on their biochemical composition and arrangement, these surface determinants may carry epitopes with distinct conformational or linear structures.
The presence of different epitopes on A. murdochii‘s antigens can trigger diverse immune responses within the host, reflecting the bacterium’s ability to interact with the immune system in nuanced ways.
The type strain of Anaerococcus murdochii, ATCC BAA-1385, was initially isolated from a human wound infection, highlighting its clinical relevance as a potential pathogen. Additionally, several other strains of A. murdochii, including CCUG 53340, JCM 15630, WAL 17230, and DSM 21462, have been deposited in various culture collections, providing valuable resources for research and diagnostic purposes.
Certain strains of A. murdochii may exhibit resistance or reduced susceptibility to specific antibiotics, such as colistin sulfate, clindamycin, and kanamycin, underscoring the importance of antibiotic susceptibility testing and appropriate treatment strategies.
Anaerococcus murdochii possesses several mechanisms that cause infections within the host. This bacterium can invade host tissues, produce a range of toxins and enzymes, form biofilms, and exhibit antibiotic resistance. A. murdochii is often isolated from skin and wound infections, where it capitalizes on reduced oxygen tension, tissue damage, and compromised host defenses.
One of the key pathogenic features of A. murdochii is its ability to produce toxins and enzymes, including lipases, proteases, hyaluronidases, and collagenases. These virulence factors can damage host tissues, leading to inflammation and necrosis, and facilitate the spread of infection.
Furthermore, A. murdochii is known to form biofilms on wound surfaces and medical devices. These biofilms serve as protective shields, shielding the bacteria from the host immune cells and antibiotics.
Additionally, biofilms can enhance adherence and colonization, often resulting in polymicrobial infections. These virulence mechanisms make A. murdochii a significant contributor to various infections, especially in vulnerable individuals or those with compromised immune systems.
The human body deploys a multifaceted arsenal of immunological mechanisms to combat Anaerococcus murdochii infections, employing various strategies to identify the most effective response. These defenses begin with physical barriers, such as the skin and mucous membranes, which aim to prevent the entry and attachment of the bacteria.
However, A. murdochii has demonstrated resistance to lysosomal enzymes, enabling it to persist within macrophages or evade the cytosol, posing a challenge to immune clearance.
In response, infected macrophages receiving cytokine signals from Th1 cells activate specific metabolic pathways, particularly oxidative metabolism, which can be hostile to intracellular bacteria. Nitric oxide production, for instance, plays a vital role in killing bacteria residing within macrophages.
Furthermore, specific immune responses, including antibodies and lymphocytes, come into play. These responses act more precisely and robustly against A. murdochii, employing strategies like neutralization, opsonization, complement activation, cytotoxicity, and memory.
Anaerococcus murdochii is frequently encountered in deep-seated anaerobic infections, encompassing soft-tissue infections, bone and joint infections, and infections affecting the female genital tracts. This bacterium has also been documented in skin and wound infection cases, demonstrating its potential to cause clinically significant conditions.
The clinical presentation of A. murdochii infections can vary widely, contingent on the site and severity of the infection. Common symptoms associated with these infections include fever, localized pain, swelling, the formation of pus, tissue necrosis, and, in severe cases, the potential development of septicemia.
Culture test: Anaerococcus murdochii can be cultured through a selective media approach can be employed. Selective media, like Bacteroides Bile Esculin (BBE) agar, can encourage anaerobic bacteria’s growth while inhibiting aerobic organisms’ growth. When attempting to isolate A. murdochii, this media should be supplemented with selective agents like bile salts, esculin, and antibiotics to discourage undesirable microbes’ growth further.
Cultures should be incubated under anaerobic conditions, typically in an anaerobic chamber. A. murdochii typically forms small, grayish-white colonies on BBE agar after incubation. These colonies may exhibit characteristic morphological features, such as being circular, convex, and opaque with an entire edge.
Phenotypic methods rely on biochemical tests, such as the Rapid ID 32A system, which can distinguish A. murdochii from other Gram-positive anaerobic cocci (GPAC) by evaluating its reactions to specific substrates. Positive responses for arginine hydrolysis, esculin hydrolysis, and acid production from sugars like glucose, maltose, mannose, and sucrose can help differentiate A. murdochii from other GPAC species.
Molecular methods offer precise identification through techniques like polymerase chain reaction (PCR) and sequencing, notably 16S rRNA gene sequencing, which can reveal A. murdochii‘s unique genetic signature. However, the availability of reference sequences and databases sometimes limits the effectiveness of these methods.
Serological tests, like enzyme-linked immunosorbent assay (ELISA) or immunofluorescence assay (IFA), aim to detect antibodies against A. murdochii in the patient’s serum or bodily fluids. Nevertheless, these tests may exhibit lower specificity and sensitivity due to potential cross-reactivity with other GPACs or bacteria.
Biomarker tests, including mass spectrometry or metabolomics, can measure specific molecules or metabolites produced by A. murdochii in patient samples. However, these tests may be influenced by the variability of bacterial metabolism and the host response.
Additionally, gas-liquid chromatography analysis of the volatile metabolic end-products generated by the bacterium can serve as a more rapid and accurate method than traditional biochemical tests for distinguishing A. murdochii from other GPACs.
Lastly, an antibiotic susceptibility test is crucial to determine the most effective antibiotic for treating the infection. It is essential because A. murdochii may display resistance or reduced susceptibility to antibiotics like colistin sulfate, clindamycin, kanamycin A, or penicillin. The results of these tests help guide clinicians in selecting the appropriate antibiotic therapy for optimal patient care.
Practicing good hygiene is fundamental. It includes thorough handwashing and proper wound care practices, especially in healthcare settings. Cleaning and covering wounds, changing dressings regularly, and maintaining a germ-free environment can help prevent infections.
Healthcare facilities should implement rigorous infection control measures, including screening, isolation of infected patients, contact precautions, sterilization of medical equipment, and surveillance.
The epidemiology of Anaerococcus murdochii remains relatively understudied, and the understanding of its prevalence is limited. This anaerobic bacterium has been documented primarily in cases of skin and wound infections. Moreover, reports of resistance or reduced susceptibility to several antibiotics, including colistin sulfate, clindamycin, kanamycin A, and penicillin, underscore the importance of careful antibiotic selection in treating A. murdochii infections.
Several studies have attempted to shed light on the occurrence of A. murdochii in clinical specimens. For instance, a study conducted in Denmark found that A. murdochii was isolated from approximately 0.4% of 1,111 clinical specimens collected from patients suspected of having anaerobic infections.
Similar studies from Japan and China reported lower isolation rates, with A. murdochii detected in approximately 0.3% of 1,200 specimens in Japan and 0.2% of 500 specimens in China. These specimens were collected from various anatomical sites, including skin, soft tissue, bone, joints, blood, and other anatomical regions. Notably, there have been no documented outbreaks or epidemics of A. murdochii infections in the literature.
Classification and Structure:
Kingdom: Bacteria
Phylum: Bacillota
Class: Clostridia
Order: Eubacteriales
Family: Peptoniphilaceae
Genus: Anaerococcus
Species: A. murdochii
Anaerococcus murdochii is a gram-positive, anaerobic coccus or GPAC pathogen commonly found in the human microbiome. Its cells are non-motile and non-spore-forming and can be arranged in pairs, tetrads, short chains, or irregular clusters.
The cell size of A. murdochii can vary, typically ranging from 0.6 μm to 0.9 μm, but it can extend from 0.5 μm to 2 μm. Major cellular fatty acids in A. murdochii include C18:1, C16:1, C18, and C16.
Anaerococcus murdochii exhibits various surface determinants, including peptidoglycan, teichoic acid, and lipoteichoic acid, essential components contributing to its structure and interaction with the host immune system. Depending on their biochemical composition and arrangement, these surface determinants may carry epitopes with distinct conformational or linear structures.
The presence of different epitopes on A. murdochii‘s antigens can trigger diverse immune responses within the host, reflecting the bacterium’s ability to interact with the immune system in nuanced ways.
The type strain of Anaerococcus murdochii, ATCC BAA-1385, was initially isolated from a human wound infection, highlighting its clinical relevance as a potential pathogen. Additionally, several other strains of A. murdochii, including CCUG 53340, JCM 15630, WAL 17230, and DSM 21462, have been deposited in various culture collections, providing valuable resources for research and diagnostic purposes.
Certain strains of A. murdochii may exhibit resistance or reduced susceptibility to specific antibiotics, such as colistin sulfate, clindamycin, and kanamycin, underscoring the importance of antibiotic susceptibility testing and appropriate treatment strategies.
Anaerococcus murdochii possesses several mechanisms that cause infections within the host. This bacterium can invade host tissues, produce a range of toxins and enzymes, form biofilms, and exhibit antibiotic resistance. A. murdochii is often isolated from skin and wound infections, where it capitalizes on reduced oxygen tension, tissue damage, and compromised host defenses.
One of the key pathogenic features of A. murdochii is its ability to produce toxins and enzymes, including lipases, proteases, hyaluronidases, and collagenases. These virulence factors can damage host tissues, leading to inflammation and necrosis, and facilitate the spread of infection.
Furthermore, A. murdochii is known to form biofilms on wound surfaces and medical devices. These biofilms serve as protective shields, shielding the bacteria from the host immune cells and antibiotics.
Additionally, biofilms can enhance adherence and colonization, often resulting in polymicrobial infections. These virulence mechanisms make A. murdochii a significant contributor to various infections, especially in vulnerable individuals or those with compromised immune systems.
The human body deploys a multifaceted arsenal of immunological mechanisms to combat Anaerococcus murdochii infections, employing various strategies to identify the most effective response. These defenses begin with physical barriers, such as the skin and mucous membranes, which aim to prevent the entry and attachment of the bacteria.
However, A. murdochii has demonstrated resistance to lysosomal enzymes, enabling it to persist within macrophages or evade the cytosol, posing a challenge to immune clearance.
In response, infected macrophages receiving cytokine signals from Th1 cells activate specific metabolic pathways, particularly oxidative metabolism, which can be hostile to intracellular bacteria. Nitric oxide production, for instance, plays a vital role in killing bacteria residing within macrophages.
Furthermore, specific immune responses, including antibodies and lymphocytes, come into play. These responses act more precisely and robustly against A. murdochii, employing strategies like neutralization, opsonization, complement activation, cytotoxicity, and memory.
Anaerococcus murdochii is frequently encountered in deep-seated anaerobic infections, encompassing soft-tissue infections, bone and joint infections, and infections affecting the female genital tracts. This bacterium has also been documented in skin and wound infection cases, demonstrating its potential to cause clinically significant conditions.
The clinical presentation of A. murdochii infections can vary widely, contingent on the site and severity of the infection. Common symptoms associated with these infections include fever, localized pain, swelling, the formation of pus, tissue necrosis, and, in severe cases, the potential development of septicemia.
Culture test: Anaerococcus murdochii can be cultured through a selective media approach can be employed. Selective media, like Bacteroides Bile Esculin (BBE) agar, can encourage anaerobic bacteria’s growth while inhibiting aerobic organisms’ growth. When attempting to isolate A. murdochii, this media should be supplemented with selective agents like bile salts, esculin, and antibiotics to discourage undesirable microbes’ growth further.
Cultures should be incubated under anaerobic conditions, typically in an anaerobic chamber. A. murdochii typically forms small, grayish-white colonies on BBE agar after incubation. These colonies may exhibit characteristic morphological features, such as being circular, convex, and opaque with an entire edge.
Phenotypic methods rely on biochemical tests, such as the Rapid ID 32A system, which can distinguish A. murdochii from other Gram-positive anaerobic cocci (GPAC) by evaluating its reactions to specific substrates. Positive responses for arginine hydrolysis, esculin hydrolysis, and acid production from sugars like glucose, maltose, mannose, and sucrose can help differentiate A. murdochii from other GPAC species.
Molecular methods offer precise identification through techniques like polymerase chain reaction (PCR) and sequencing, notably 16S rRNA gene sequencing, which can reveal A. murdochii‘s unique genetic signature. However, the availability of reference sequences and databases sometimes limits the effectiveness of these methods.
Serological tests, like enzyme-linked immunosorbent assay (ELISA) or immunofluorescence assay (IFA), aim to detect antibodies against A. murdochii in the patient’s serum or bodily fluids. Nevertheless, these tests may exhibit lower specificity and sensitivity due to potential cross-reactivity with other GPACs or bacteria.
Biomarker tests, including mass spectrometry or metabolomics, can measure specific molecules or metabolites produced by A. murdochii in patient samples. However, these tests may be influenced by the variability of bacterial metabolism and the host response.
Additionally, gas-liquid chromatography analysis of the volatile metabolic end-products generated by the bacterium can serve as a more rapid and accurate method than traditional biochemical tests for distinguishing A. murdochii from other GPACs.
Lastly, an antibiotic susceptibility test is crucial to determine the most effective antibiotic for treating the infection. It is essential because A. murdochii may display resistance or reduced susceptibility to antibiotics like colistin sulfate, clindamycin, kanamycin A, or penicillin. The results of these tests help guide clinicians in selecting the appropriate antibiotic therapy for optimal patient care.
Practicing good hygiene is fundamental. It includes thorough handwashing and proper wound care practices, especially in healthcare settings. Cleaning and covering wounds, changing dressings regularly, and maintaining a germ-free environment can help prevent infections.
Healthcare facilities should implement rigorous infection control measures, including screening, isolation of infected patients, contact precautions, sterilization of medical equipment, and surveillance.
The epidemiology of Anaerococcus murdochii remains relatively understudied, and the understanding of its prevalence is limited. This anaerobic bacterium has been documented primarily in cases of skin and wound infections. Moreover, reports of resistance or reduced susceptibility to several antibiotics, including colistin sulfate, clindamycin, kanamycin A, and penicillin, underscore the importance of careful antibiotic selection in treating A. murdochii infections.
Several studies have attempted to shed light on the occurrence of A. murdochii in clinical specimens. For instance, a study conducted in Denmark found that A. murdochii was isolated from approximately 0.4% of 1,111 clinical specimens collected from patients suspected of having anaerobic infections.
Similar studies from Japan and China reported lower isolation rates, with A. murdochii detected in approximately 0.3% of 1,200 specimens in Japan and 0.2% of 500 specimens in China. These specimens were collected from various anatomical sites, including skin, soft tissue, bone, joints, blood, and other anatomical regions. Notably, there have been no documented outbreaks or epidemics of A. murdochii infections in the literature.
Classification and Structure:
Kingdom: Bacteria
Phylum: Bacillota
Class: Clostridia
Order: Eubacteriales
Family: Peptoniphilaceae
Genus: Anaerococcus
Species: A. murdochii
Anaerococcus murdochii is a gram-positive, anaerobic coccus or GPAC pathogen commonly found in the human microbiome. Its cells are non-motile and non-spore-forming and can be arranged in pairs, tetrads, short chains, or irregular clusters.
The cell size of A. murdochii can vary, typically ranging from 0.6 μm to 0.9 μm, but it can extend from 0.5 μm to 2 μm. Major cellular fatty acids in A. murdochii include C18:1, C16:1, C18, and C16.
Anaerococcus murdochii exhibits various surface determinants, including peptidoglycan, teichoic acid, and lipoteichoic acid, essential components contributing to its structure and interaction with the host immune system. Depending on their biochemical composition and arrangement, these surface determinants may carry epitopes with distinct conformational or linear structures.
The presence of different epitopes on A. murdochii‘s antigens can trigger diverse immune responses within the host, reflecting the bacterium’s ability to interact with the immune system in nuanced ways.
The type strain of Anaerococcus murdochii, ATCC BAA-1385, was initially isolated from a human wound infection, highlighting its clinical relevance as a potential pathogen. Additionally, several other strains of A. murdochii, including CCUG 53340, JCM 15630, WAL 17230, and DSM 21462, have been deposited in various culture collections, providing valuable resources for research and diagnostic purposes.
Certain strains of A. murdochii may exhibit resistance or reduced susceptibility to specific antibiotics, such as colistin sulfate, clindamycin, and kanamycin, underscoring the importance of antibiotic susceptibility testing and appropriate treatment strategies.
Anaerococcus murdochii possesses several mechanisms that cause infections within the host. This bacterium can invade host tissues, produce a range of toxins and enzymes, form biofilms, and exhibit antibiotic resistance. A. murdochii is often isolated from skin and wound infections, where it capitalizes on reduced oxygen tension, tissue damage, and compromised host defenses.
One of the key pathogenic features of A. murdochii is its ability to produce toxins and enzymes, including lipases, proteases, hyaluronidases, and collagenases. These virulence factors can damage host tissues, leading to inflammation and necrosis, and facilitate the spread of infection.
Furthermore, A. murdochii is known to form biofilms on wound surfaces and medical devices. These biofilms serve as protective shields, shielding the bacteria from the host immune cells and antibiotics.
Additionally, biofilms can enhance adherence and colonization, often resulting in polymicrobial infections. These virulence mechanisms make A. murdochii a significant contributor to various infections, especially in vulnerable individuals or those with compromised immune systems.
The human body deploys a multifaceted arsenal of immunological mechanisms to combat Anaerococcus murdochii infections, employing various strategies to identify the most effective response. These defenses begin with physical barriers, such as the skin and mucous membranes, which aim to prevent the entry and attachment of the bacteria.
However, A. murdochii has demonstrated resistance to lysosomal enzymes, enabling it to persist within macrophages or evade the cytosol, posing a challenge to immune clearance.
In response, infected macrophages receiving cytokine signals from Th1 cells activate specific metabolic pathways, particularly oxidative metabolism, which can be hostile to intracellular bacteria. Nitric oxide production, for instance, plays a vital role in killing bacteria residing within macrophages.
Furthermore, specific immune responses, including antibodies and lymphocytes, come into play. These responses act more precisely and robustly against A. murdochii, employing strategies like neutralization, opsonization, complement activation, cytotoxicity, and memory.
Anaerococcus murdochii is frequently encountered in deep-seated anaerobic infections, encompassing soft-tissue infections, bone and joint infections, and infections affecting the female genital tracts. This bacterium has also been documented in skin and wound infection cases, demonstrating its potential to cause clinically significant conditions.
The clinical presentation of A. murdochii infections can vary widely, contingent on the site and severity of the infection. Common symptoms associated with these infections include fever, localized pain, swelling, the formation of pus, tissue necrosis, and, in severe cases, the potential development of septicemia.
Culture test: Anaerococcus murdochii can be cultured through a selective media approach can be employed. Selective media, like Bacteroides Bile Esculin (BBE) agar, can encourage anaerobic bacteria’s growth while inhibiting aerobic organisms’ growth. When attempting to isolate A. murdochii, this media should be supplemented with selective agents like bile salts, esculin, and antibiotics to discourage undesirable microbes’ growth further.
Cultures should be incubated under anaerobic conditions, typically in an anaerobic chamber. A. murdochii typically forms small, grayish-white colonies on BBE agar after incubation. These colonies may exhibit characteristic morphological features, such as being circular, convex, and opaque with an entire edge.
Phenotypic methods rely on biochemical tests, such as the Rapid ID 32A system, which can distinguish A. murdochii from other Gram-positive anaerobic cocci (GPAC) by evaluating its reactions to specific substrates. Positive responses for arginine hydrolysis, esculin hydrolysis, and acid production from sugars like glucose, maltose, mannose, and sucrose can help differentiate A. murdochii from other GPAC species.
Molecular methods offer precise identification through techniques like polymerase chain reaction (PCR) and sequencing, notably 16S rRNA gene sequencing, which can reveal A. murdochii‘s unique genetic signature. However, the availability of reference sequences and databases sometimes limits the effectiveness of these methods.
Serological tests, like enzyme-linked immunosorbent assay (ELISA) or immunofluorescence assay (IFA), aim to detect antibodies against A. murdochii in the patient’s serum or bodily fluids. Nevertheless, these tests may exhibit lower specificity and sensitivity due to potential cross-reactivity with other GPACs or bacteria.
Biomarker tests, including mass spectrometry or metabolomics, can measure specific molecules or metabolites produced by A. murdochii in patient samples. However, these tests may be influenced by the variability of bacterial metabolism and the host response.
Additionally, gas-liquid chromatography analysis of the volatile metabolic end-products generated by the bacterium can serve as a more rapid and accurate method than traditional biochemical tests for distinguishing A. murdochii from other GPACs.
Lastly, an antibiotic susceptibility test is crucial to determine the most effective antibiotic for treating the infection. It is essential because A. murdochii may display resistance or reduced susceptibility to antibiotics like colistin sulfate, clindamycin, kanamycin A, or penicillin. The results of these tests help guide clinicians in selecting the appropriate antibiotic therapy for optimal patient care.
Practicing good hygiene is fundamental. It includes thorough handwashing and proper wound care practices, especially in healthcare settings. Cleaning and covering wounds, changing dressings regularly, and maintaining a germ-free environment can help prevent infections.
Healthcare facilities should implement rigorous infection control measures, including screening, isolation of infected patients, contact precautions, sterilization of medical equipment, and surveillance.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
